In the 21st century, the rate at which cases of a disease can spread across the world is unprecedented, as highlighted by the 2019-2020 COVID-19 (SARS-CoV-2) pandemic, with daily confirmed cases in the UK rising exponentially (12 confirmed on the 1st March 2020, and 3,634 on the 7th April, Public Health England). This rapid growth exemplifies the urgent and increasing need for rapid development of readily available, high performing diagnostic tools, to support global efforts in controlling the pandemic.
As stated by the World Health Organization (COVID-19 Situation report 63), diagnostic testing for COVID-19 is critical to track the virus, understand epidemiology, inform case management and to suppress transmission. With COVID-19 symptoms not easily distinguishable from the common cold and flu, population screening paired with conclusive diagnostic testing is one of the most effective methods to control the spread of infection, enabling earlier quarantine and treatment.
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.